Abstract:Thymic carcinomas (TC) are remarkably rare aggressive tumors. Due to this, the optimal first-line regimen in patients with advanced TC has not been clarified since the previous studies included a relatively small number of TC patients. The purpose of this study was to evaluate the optimal first-line regimen in patients with advanced TC. We conducted a retrospective study in patients with advanced TC from 2006 to 2015. The primary end point of this study was to evaluate the objective response rate (ORR) and progression free survival (PFS) of different chemotherapy regimens. Age, gender, stage (IVa or IVb), radiation therapy after chemotherapy, resection of primary lesion, different chemotherapy regimens and cycles of chemotherapy were analyzed for significance on PFS. Multivariate Cox model was used to identify significant factors. Sixty-seven patients with stage IV (Masaoka stage) TC were enrolled. Thirty-six patients were treated with paclitaxel-platinum regimen every 3 weeks for a maximum of six cycles. Thirty-one patients were treated with gemcitabine-platinum regimen every 3 weeks for a maximum of six cycles. Resections of primary lesion were performed in fourteen patients before chemotherapy. Thirty-three out of 67 patients were given radiation therapy after chemotherapy. Multivariate analysis demonstrated that different stages (HR = 2.47, P = 0.003), surgical resection (HR = 0.32, P= 0.0049) and radiation therapy after chemotherapy (HR = 0.32, P= 0.0001) were significantly associated with PFS. The ORR were 31% (11/36) and 29% (9/31) in paclitaxel-platinum regimen group and gemcitabine-platinum regimen group (P=0.89), respectively. The median PFS, 1-/2-year PFS rates in paclitaxel-platinum regimen group were 7.0 (95% CI 4.0–8.0) months, 26%/6% respectively compared to 12 months (95% CI 11.2–24.0), 48%/24% in gemcitabine-platinum regimen group (P=0.03). The median PFS, 1-/2-year PFS rates were 18.0 (95% CI 12.0–36.0) months/7.3(95% CI 5.0–11.3) months, 57%/31% and 33%/7% for patients with and without resection of primary lesion (P = 0.0302). The median PFS, 1-/2-year PFS rates were 13.0 (95% CI 11.3–17.0) months/4.3(95% CI 3.0–7.3)months, 52%/22% and 20%/7% for patients with and without radiation after chemotherapy (P = 0.0013). Major adverse event was grade 3–4 neutropenia in both paclitaxel-platinum regimen (27.7%) and gemcitabine-platinum regimen group (12.9%). Grade 1-2 sensory neuropathy and/or muscle pain were seen in 25.0% of patients treated with paclitaxel-platinum regimen. Both gemcitabine-platinum and paclitaxel-platinum regimen showed promising efficacy in advanced TC. Resections of primary lesion and radiation after chemotherapy might be an option for selected patients.

Efficacy and Toxicities of Gemcitabine and Cisplatin Combination Chemotherapy in Advanced Thymoma and Thymic Carcinoma.

Efficacy and Toxicities of Gemcitabine and Cisplatin Combined with Endostar in Advanced Thymoma and Thymic Carcinoma

A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Curative Effect of Gemcitabine Combined with Platinum Drugs on Treatment of Advanced Squamous Carcinoma and Adenocarcinoma of Lung

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Clinical trial of advanced non-small cell lung cancer by combination of gemci-tabine and cisplatin

Outcome of Advanced Nonsmall Cell Lung Cancer Patients Receiving Gemcitabine and Weekly Paclitaxel As First-Line Treatment

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

P5-19-06: Highly Effective of Gemcitabine and Cisplatin (GP) As First-Line Combination Therapy in Patients with Triple-Negative Metastatic Breast Cancer: Final Report of a Phase II Trial.

Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

Retrospective Study of Gemcitabine Based Chemotherapy for Unresectable or Recurrent Esophagus Squamous Cell Carcinoma Refractory to First Line Chemotherapy

The efficacy and toxicity of gemcitabine combined with cisplatin for advanced bladder cancer

Efficacy of Combined Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

A Phase II Trial of Gemcitabine Plus Carboplatin in Advanced Transitional Cell Carcinoma of the Urothelium

Characteristics and Outcome of Systemic Treatment for Metastatic or Unresectable Thymic Carcinoma: A Single Institution Experience.

P1.17-001 the Optimal First-Line Treatment for Advanced Thymic Carcinomas

A trial of gemcitabine (gems) in combination with cisplatin for treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

Efficacy Of Gemcitabine And Cisplatin (Gp) As First-Line Combination Therapy In Patients With Triple-Negative Metastatic Breast Cancer: Prclineinary Results Report Of A Phase Ii Trial

Efficacy of Docetaxel Combined with Cisplatin in the Treatment of Advanced Thymic Carcinoma

[Efficacy of Gemcitabine-Based Chemotherapy on Advanced Pancreatic Cancer].

Gemcitabine Plus Cisplatin Combination in the Treatment of 16 Cases with Advanced Non Small Cell Lung Cancer